Recruiting
Phase 1

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Sponsor:

City of Hope Medical Center

Code:

NCT06498973

Conditions

Acute Myeloid Leukemia

Myelodysplastic Syndrome

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Azacitidine

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Questionnaire Administration

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information